Global Veterinary Intravenous (IV) Solutions Market Outlook 2025-2034: Trends, Innovations, And Future Outlook

The Veterinary Intravenous (IV) Solutions Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Veterinary Intravenous (IV) Solutions Market Size and Projected Growth Rate?
The market size for veterinary intravenous (IV) solutions has seen significant growth in the recent past. The predictions indicate a rise from $1.5 billion in 2024 to $1.62 billion in 2025, showing a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the historic period include a surge in the establishment of veterinary clinics, an increase in dehydration cases, expansion in livestock farming, an upswing in the population of companion animals, and development in the field of veterinary diagnostics.

In the forthcoming years, the market for veterinary intravenous (IV) solutions is slated for substantial expansion. With a CAGR of 7.8%, it's projected to reach $2.19 billion in 2029. This growth during the forecast period can be ascribed to an upsurge in pet insurance adoption, escalation of animal healthcare spending, heightened consciousness about animal health, increasing instances of animal diseases, and extended coverage of pet insurance. Trending advancements in technology, various product formulations, incorporation of telemedicine, sophisticated veterinary intravenous (IV) delivery mechanisms, and intelligent veterinary intravenous (IV) systems are expected to define the forecast period.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20686

What Are the Major Segments in the Veterinary Intravenous (IV) Solutions Market?
The veterinary intravenous (IV) solutions market covered in this report is segmented -

1) By Product: Isotonic Crystalloids, Dextrose Solutions, Synthetic Colloids, Natural Colloids, Parenteral Nutrition
2) By Animal Type: Companion Animals, Production Animals
3) By End-User: Veterinary Hospitals And Clinics, Research Institutes, Other End-Users

Subsegments:
1) Isotonic Crystalloids: Normal Saline (0.9% NaCl), Lactated Ringer's Solution, Dextrose in Water (D5W), Ringer's Solution, Balanced Electrolyte Solutions
2) Dextrose Solutions: Dextrose 5% in Water (D5W), Dextrose 10% in Water (D10W), Dextrose 20% in Water (D20W), Dextrose 50% in Water (D50W)
3) Synthetic Colloids: Hydroxyethyl Starch (HES), Dextran, Gelatins
4) Natural Colloids: Albumin, Fresh Frozen Plasma (FFP), Blood Products
5) Parenteral Nutrition: Total Parenteral Nutrition (TPN) Solutions, Partial Parenteral Nutrition Solutions, Lipid Emulsions, Amino Acid Solutions

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20686&type=smp

What Are The Driving Veterinary Intravenous (IV) Solutions Market Evolution?
The upward trend in the occurrence of various animal diseases is set to catalyze the expansion of the veterinary intravenous (IV) solutions market. These diseases not only affect the health of animals but also hinder their functionality. Some prevalent diseases include anthrax, leptospirosis, rabies, canine distemper, heartworm disease, among others. This increase in disease prevalence is spurred by factors such as intensive farming procedures, intrusion of wildlife, and resistance to antibiotics. Veterinary IV solutions play a vital role in reviving animals suffering from diseases that cause severe dehydration like gastroenteritis or extreme infections. These solutions ensure the correct level of hydration thereby improving overall health outcomes. AVMA Publications, a publishing wing of the American Veterinary Medical Association, reported in July 2024 that around 345 domestic animals had tested positive for rabies in 2022. This figure represents a 10.9% increase as compared to the 311 cases reported in the previous year. This increased prevalence of various animal diseases is contributing to the expansion of the veterinary intravenous (IV) solutions market. Veterinary IV solutions are set to see major growth, largely fuelled by the rise in expenditure on animal health products. These health products include medicines, nutritional supplements, and treatments intended to uphold or enhance an animal's health and wellness. The augmenting expenses on such products can be accredited to a myriad of factors, including increasing pet ownership, heightened awareness about animal health, developments in veterinary care, and a demand for superior disease prevention & treatment options. IV solutions for animals help cater to immediate medical needs and allow for advancements in veterinary care. As an exemplification, according to reports from The Republic of Estonia Agency of Medicines in March 2024, the veterinary medicinal products market witnessed a 6.9% growth in 2023, soaring to $20.54 million (18.6 million euros) from $19.21 million (17.40 million euros) noted in the preceding year. Hence, the rising expenditure on animal health products is fuelling the growth of the veterinary IV solutions market.

Which Firms Dominate The Veterinary Intravenous (IV) Solutions Market Segments?
Major companies operating in the veterinary intravenous (IV) solutions market are Merck & Co. Inc., Baxter International Inc., Zoetis Inc., Fresenius Kabi AG, Elanco Animal Health Incorporated, B. Braun Melsungen AG, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol SA, Norbrook Laboratories Limited, Ceva Santé Animale, Revival Animal Health Inc., Aromor Animal Health, Jorgensen Laboratories LLC, Pharmacosmos AS, Sykes Veterinary International Pty Ltd., Rusoma Laboratories Private Limited, Patterson Companies Inc., NexGen Veterinary, Soxa Formulations & Research Pvt. Ltd

What Trends Are Expected to Dominate the Amnion Patch Market in the Next 5 Years?
Major businesses in the veterinary intravenous (IV) solutions sector are turning their focus on the creation of superior products like fluoroquinolones to enhance efficiency and safety profiles. Fluoroquinolones belong to a robust group of antibiotics utilized in both human and veterinary medicine to address various bacterial infections, and with careful management, the risk of resistance and adverse reactions can be reduced. For example, in April 2024, Elanco, an American pharmaceutical firm, announced the approval of Pradalex, a pradofloxacin injection solution, by the US Food and Drug Administration (FDA), an American health institution. This approval is specific to swine for addressing swine respiratory disease (SRD) linked with several bacteria such as bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, streptococcus suis, and mycoplasma hyopneumoniae. Regarded as a critically important antimicrobial, Pradalex is a third-generation fluoroquinolone, and its label advises that other non-fluoroquinolone therapeutic alternatives should be considered before use.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/veterinary-intravenous-iv-solutions-global-market-report

Which Is The Largest Region In The Veterinary Intravenous (IV) Solutions Market?
North America was the largest region in the veterinary intravenous (IV) solutions market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary intravenous (IV) solutions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Veterinary Intravenous (IV) Solutions Market?
2. What is the CAGR expected in the Veterinary Intravenous (IV) Solutions Market?
3. What Are the Key Innovations Transforming the Veterinary Intravenous (IV) Solutions Industry?
4. Which Region Is Leading the Veterinary Intravenous (IV) Solutions Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the veterinary intravenous (iv) solutions market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.